Enrollment Trends Among Patients with Melanoma Brain Metastasis in Active Clinical Trials

References

• Saginala K, Barsouk A, Aluru JS, Rawla P, Barsouk A. Epidemiology of melanoma. Med. Sci. 2021;9:63.
   Google Scholar
• Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S. Evolving treatment options for melanoma brain metastases. Lancet Oncol. 2015;16(13):e486–e497. doi:10.1016/S1470-2045(15)00141-2.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Melanoma of the skin-cancer stat facts. https://seer.cancer.gov/statfacts/html/ melan.html.
   Google Scholar
• Janavicius M, Lachej N, Anglickiene G, Vincerzevskiene I, Brasiuniene B. Outcomes of treatment for melanoma brain metastases. J. Skin Cancer. 2020;2020:1–10.
   Web of Science ®Google Scholar
• Differences between Australia (OZ) and the United States (US) in the patterns, prognosis, and treatment of melanoma CNS metastases: analysis from the PHAMOUS (prognostic heterogeneity in patients with advanced melanoma between OZ and the US) study Melanoma 2010 Congress. Pigment Cell Melanoma Res. 2010;23:874–1004.
   Google Scholar
• Lamba N, Wen PY, Aizer AA. Epidemiology of brain metastases and leptomeningeal disease. Neuro Oncol. 2021;23(9):1447–1456. doi:10.1093/neuonc/noab101.
   PubMed Web of Science ®Google Scholar
• de la Monte SM, Moore GW, Hutchins GM. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res. 1983;43(7):3427–3433.
   PubMed Web of Science ®Google Scholar
• Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. Am J Surg. 1978;135(6):807–810. doi:10.1016/0002-9610(78)90171-x.
   PubMed Web of Science ®Google Scholar
• Damsky WE, Rosenbaum LE, Bosenberg M. Decoding melanoma metastasis. Cancers. 2010;3(1):126–163. doi:10.3390/cancers3010126.
   PubMedGoogle Scholar
• Frenard C, Peuvrel L, Jean MS, Brocard A, Knol AC, Nguyen JM, et al. Development of brain metastases in patients with metastatic melanoma while receiving ipilimumab. J Neurooncol. 2016;126(2):355–360. doi:10.1007/s11060-015-1977-9.
   PubMed Web of Science ®Google Scholar
• Gibney GT, et al. Treatment patterns and outcomes in BRAF V600E‐mutant melanoma patients with brain metastases receiving vemurafenib in the real‐world setting. Cancer Med. 2015;4:1205–1213.
   PubMed Web of Science ®Google Scholar
• Lin NU, et al. Modernizing clinical trial eligibility criteria: recommendations of the American society of clinical oncology–friends of cancer research brain metastases working group. J. Clin. Oncol. 2017;35:3760–3773.
   PubMed Web of Science ®Google Scholar
• Quéreux G, Dréno B. Fotemustine for the treatment of melanoma. Expert Opin Pharmacother. 2011;12(18):2891–2904. doi:10.1517/14656566.2011.633513.
   PubMed Web of Science ®Google Scholar
• Larkin JMG, Hughes SA, Beirne DA, Patel PM, Gibbens IM, Bate SC, et al. A Phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma. Br J Cancer. 2007;96(1):44–48.
   PubMed Web of Science ®Google Scholar
• Tawbi H, et al. Treatment patterns and clinical outcomes for patients with melanoma and central nervous system metastases: a real‐world study. Cancer Med. 2022;11:139–150.
   PubMed Web of Science ®Google Scholar
• Minniti G, Paolini S, D’Andrea G, Lanzetta G, Cicone F, Confaloni V, et al. Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases. J Neurooncol. 2017;132(3):455–462. doi:10.1007/s11060-017-2394-z.
   PubMed Web of Science ®Google Scholar
• Bagshaw HP, Ly D, Suneja G, Jensen RL, Shrieve DC. Local control of melanoma brain metastases treated with stereotactic radiosurgery. J Radiosurg Sbrt. 2016;4(3):181–190.
   PubMedGoogle Scholar
• Fiore G, Tariciotti L, Bertani GA, Gagliano D, D’Ammando A, Ampollini AM, et al. Surgery vs. radiosurgery for patients with localized metastatic brain disease: a systematic review with meta-analysis of randomized controlled trials. Cancers. 2023;15(15):3802. doi:10.3390/cancers15153802.
   PubMed Web of Science ®Google Scholar
• Sood S, Jayachandiran R, Pandey S. Current advancements and novel strategies in the treatment of metastatic melanoma. Integr. Cancer Ther. 2021;20:153473542199007.
   Web of Science ®Google Scholar
• Glitza Oliva I, Tawbi H, Davies MA. Melanoma brain metastases: current areas of investigation and future directions. Cancer J. Sudbury Mass. 2017;23(1):68–74. doi:10.1097/PPO.0000000000000237.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Hodi FS, Robert C, Weber JS, Margolin K, Hamid O, et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol. 2015;33(17):1889–1894. doi:10.1200/JCO.2014.56.2736.
   PubMed Web of Science ®Google Scholar
• Long GV, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672–681.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546.
   PubMed Web of Science ®Google Scholar
• Davies MA, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18:863–873.
   PubMed Web of Science ®Google Scholar
• Caulfield JI, Kluger HM. Emerging studies of melanoma brain metastasis. Curr Oncol Rep. 2022;24(5):585–594. doi:10.1007/s11912-022-01237-9.
   PubMed Web of Science ®Google Scholar
• Flanigan JC, et al. Melanoma brain metastases: Is it time to reassess the bias? Curr Probl. Cancer. 2011;35:200–210.
   PubMed Web of Science ®Google Scholar
• Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, et al. Melanoma central nervous system metastases: current approaches, challenges, and opportunities. Pigment Cell Melanoma Res. 2016;29(6):627–642. doi:10.1111/pcmr.12538.
   PubMed Web of Science ®Google Scholar
• McCoach CE, Berge EM, Lu X, Barón AE, Camidge DR. A brief report of the status of central nervous system metastasis enrollment criteria for advanced non–small cell lung cancer clinical trials: a review of the clinicaltrials.gov trial registry. J Thorac Oncol. 2016;11(3):407–413. doi:10.1016/j.jtho.2015.10.024.
   PubMed Web of Science ®Google Scholar
• Costa R, et al. Systematic analysis of early phase clinical studies for patients with breast cancer: inclusion of patients with brain metastasis. Cancer Treat. Rev. 2017;55:10–15.
   PubMed Web of Science ®Google Scholar
• Pan Z, et al. Leptomeningeal metastases from a primary central nervous system melanoma: a case report and literature review. World J. Surg. Oncol. 2014;12:265.
   PubMed Web of Science ®Google Scholar
• Smalley KSM, Fedorenko IV, Kenchappa RS, Sahebjam S, Forsyth PA. Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy: leptomeningeal melanoma metastases. Int J Cancer. 2016;139(6):1195–1201. doi:10.1002/ijc.30147.
   PubMed Web of Science ®Google Scholar
• Patel RR, Verma V, Miller AB, Lin TA, Jethanandani A, Espinoza AF, et al. Exclusion of patients with brain metastases from cancer clinical trials. Neuro-Oncol. 2020;22(4):577–579. doi:10.1093/neuonc/noz246.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021;22:1692–1704.
   PubMed Web of Science ®Google Scholar